SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Rachel L. Nosheny, Philip S. Insel, Diana Truran, Norbert Schuff, Clifford R. Jack, Paul S. Aisen, Leslie M. Shaw, John Q. Trojanowski, Michael W. Weiner, Variables associated with hippocampal atrophy rate in normal aging and mild cognitive impairment, Neurobiology of Aging, 2015, 36, 1, 273

    CrossRef

  2. 2
    A. L. Young, N. P. Oxtoby, P. Daga, D. M. Cash, N. C. Fox, S. Ourselin, J. M. Schott, D. C. Alexander, A data-driven model of biomarker changes in sporadic Alzheimer's disease, Brain, 2014, 137, 9, 2564

    CrossRef

  3. 3
    Ruth Gasparini Berenguer, José Antonio Monge Argilés, Carlos Muñoz Ruiz, José Sánchez Payá, María Amparo Blanco Cantó, Carlos Leiva Santana, Alzheimer Disease Cerebrospinal Fluid Biomarkers Predict Cognitive Decline In Healthy Elderly Over 2 Years, Alzheimer Disease & Associated Disorders, 2014, 28, 3, 234

    CrossRef

  4. 4
    Ross W. Paterson, Jamie Toombs, Catherine F. Slattery, Jonathan M. Schott, Henrik Zetterberg, Biomarker Modelling of Early Molecular Changes in Alzheimer’s Disease, Molecular Diagnosis & Therapy, 2014, 18, 2, 213

    CrossRef

  5. 5
    Niklas Mattsson, Philip Insel, Rachel Nosheny, John Q. Trojanowski, Leslie M. Shaw, Clifford R. Jack, Duygu Tosun, Michael Weiner, Effects of cerebrospinal fluid proteins on brain atrophy rates in cognitively healthy older adults, Neurobiology of Aging, 2014, 35, 3, 614

    CrossRef

  6. 6
    Duygu Tosun, Sarang Joshi, Michael W. Weiner, Multimodal MRI-based imputation of the Aβ+ in early mild cognitive impairment, Annals of Clinical and Translational Neurology, 2014, 1, 3
  7. 7
    Daniela Bertens, Dirk L. Knol, Philip Scheltens, Pieter Jelle Visser, Temporal evolution of biomarkers and cognitive markers in the asymptomatic, MCI, and dementia stage of Alzheimer's disease, Alzheimer's & Dementia, 2014,

    CrossRef

  8. 8
    Reisa Sperling, Elizabeth Mormino, Keith Johnson, The Evolution of Preclinical Alzheimer’s Disease: Implications for Prevention Trials, Neuron, 2014, 84, 3, 608

    CrossRef

  9. 9
    Elizabeth C. Mormino, The Relevance of Beta-Amyloid on Markers of Alzheimer’s Disease in Clinically Normal Individuals and Factors That Influence These Associations, Neuropsychology Review, 2014, 24, 3, 300

    CrossRef

  10. 10
    Henrik Zetterberg, Niklas Mattsson, Understanding the cause of sporadic Alzheimer’s disease, Expert Review of Neurotherapeutics, 2014, 14, 6, 621

    CrossRef

  11. 11
    Anders M. Fjell, Linda McEvoy, Dominic Holland, Anders M. Dale, Kristine B. Walhovd, What is normal in normal aging? Effects of aging, amyloid and Alzheimer's disease on the cerebral cortex and the hippocampus, Progress in Neurobiology, 2014, 117, 20

    CrossRef

  12. 12
    Gaël Chételat, Renaud La Joie, Nicolas Villain, Audrey Perrotin, Vincent de La Sayette, Francis Eustache, Rik Vandenberghe, Amyloid imaging in cognitively normal individuals, at-risk populations and preclinical Alzheimer's disease, NeuroImage: Clinical, 2013, 2, 356

    CrossRef

  13. 13
    R. S. Desikan, M. S. Rafii, J. B. Brewer, C. P. Hess, An Expanded Role for Neuroimaging in the Evaluation of Memory Impairment, American Journal of Neuroradiology, 2013, 34, 11, 2075

    CrossRef

  14. 14
    R. S. Desikan, L. K. McEvoy, D. Holland, W. K. Thompson, J. B. Brewer, P. S. Aisen, O. A. Andreassen, B. T. Hyman, R. A. Sperling, A. M. Dale, Apolipoprotein E  4 Does Not Modulate Amyloid- -Associated Neurodegeneration in Preclinical Alzheimer Disease, American Journal of Neuroradiology, 2013, 34, 3, 505

    CrossRef

  15. 15
    P. Edison, S.F. Carter, J.O. Rinne, G. Gelosa, K. Herholz, A. Nordberg, D.J. Brooks, R. Hinz, Comparison of MRI based and PET template based approaches in the quantitative analysis of amyloid imaging with PIB-PET, NeuroImage, 2013, 70, 423

    CrossRef

  16. 16
    Joshua D. Grill, Lijie Di, Po H. Lu, Cathy Lee, John Ringman, Liana G. Apostolova, Nicole Chow, Omid Kohannim, Jeffrey L. Cummings, Paul M. Thompson, David Elashoff, Estimating sample sizes for predementia Alzheimer's trials based on the Alzheimer's Disease Neuroimaging Initiative, Neurobiology of Aging, 2013, 34, 1, 62

    CrossRef

  17. 17
    Christoffer Rosén, Oskar Hansson, Kaj Blennow, Henrik Zetterberg, Fluid biomarkers in Alzheimer’s disease – current concepts, Molecular Neurodegeneration, 2013, 8, 1, 20

    CrossRef

  18. 18
    Michael W. Weiner, Dallas P. Veitch, Paul S. Aisen, Laurel A. Beckett, Nigel J. Cairns, Robert C. Green, Danielle Harvey, Clifford R. Jack, William Jagust, Enchi Liu, John C. Morris, Ronald C. Petersen, Andrew J. Saykin, Mark E. Schmidt, Leslie Shaw, Li Shen, Judith A. Siuciak, Holly Soares, Arthur W. Toga, John Q. Trojanowski, The Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception, Alzheimer's & Dementia, 2013, 9, 5, e111

    CrossRef

  19. 19
    Josephine Barnes, Owen T. Carmichael, Kelvin K. Leung, Christopher Schwarz, Gerard R. Ridgway, Jonathan W. Bartlett, Ian B. Malone, Jonathan M. Schott, Martin N. Rossor, Geert Jan Biessels, Charlie DeCarli, Nick C. Fox, Vascular and Alzheimer's disease markers independently predict brain atrophy rate in Alzheimer's Disease Neuroimaging Initiative controls, Neurobiology of Aging, 2013, 34, 8, 1996

    CrossRef

  20. 20
    Gerald Novak, Steven G. Einstein, Translational Neuroimaging, 2013,

    CrossRef

  21. 21
    Clifford R. Jack, David S. Knopman, Stephen D. Weigand, Heather J. Wiste, Prashanthi Vemuri, Val Lowe, Kejal Kantarci, Jeffrey L. Gunter, Matthew L. Senjem, Robert J. Ivnik, Rosebud O. Roberts, Walter A. Rocca, Bradley F. Boeve, Ronald C. Petersen, An operational approach to National Institute on Aging–Alzheimer's Association criteria for preclinical Alzheimer disease, Annals of Neurology, 2012, 71, 6
  22. 22
    David S Knopman, Richard J Caselli, Appraisal of cognition in preclinical Alzheimer’s disease: a conceptual review, Neurodegenerative Disease Management, 2012, 2, 2, 183

    CrossRef

  23. 23
    M. Ewers, P. Insel, W. J. Jagust, L. Shaw, J. Q. Trojanowski J, P. Aisen, R. C. Petersen, N. Schuff, M. W. Weiner, CSF Biomarker and PIB-PET-Derived Beta-Amyloid Signature Predicts Metabolic, Gray Matter, and Cognitive Changes in Nondemented Subjects, Cerebral Cortex, 2012, 22, 9, 1993

    CrossRef

  24. 24
    Jonathan W Bartlett, Chris Frost, Niklas Mattsson, Tobias Skillbäck, Kaj Blennow, Henrik Zetterberg, Jonathan M Schott, Determining cut-points for Alzheimer’s disease biomarkers: statistical issues, methods and challenges, Biomarkers in Medicine, 2012, 6, 4, 391

    CrossRef

  25. 25
    Maciej J Lazarczyk, Patrick R Hof, Constantin Bouras, Panteleimon Giannakopoulos, Preclinical Alzheimer disease: identification of cases at risk among cognitively intact older individuals, BMC Medicine, 2012, 10, 1, 127

    CrossRef

  26. 26
    Michael W. Weiner, Dallas P. Veitch, Paul S. Aisen, Laurel A. Beckett, Nigel J. Cairns, Robert C. Green, Danielle Harvey, Clifford R. Jack, William Jagust, Enchi Liu, John C. Morris, Ronald C. Petersen, Andrew J. Saykin, Mark E. Schmidt, Leslie Shaw, Judith A. Siuciak, Holly Soares, Arthur W. Toga, John Q. Trojanowski, The Alzheimer’s Disease Neuroimaging Initiative: A review of papers published since its inception, Alzheimer's & Dementia, 2012, 8, 1, S1

    CrossRef

  27. 27
    M. R. Sabuncu, R. L. Buckner, J. W. Smoller, P. H. Lee, B. Fischl, R. A. Sperling, The Association between a Polygenic Alzheimer Score and Cortical Thickness in Clinically Normal Subjects, Cerebral Cortex, 2012, 22, 11, 2653

    CrossRef

  28. 28
    Dominic Holland, Linda K. McEvoy, Anders M. Dale, Unbiased comparison of sample size estimates from longitudinal structural measures in ADNI, Human Brain Mapping, 2012, 33, 11
  29. 29
    Jonathan M. Schott, Using CSF biomarkers to replicate genetic associations in Alzheimer's disease, Neurobiology of Aging, 2012, 33, 7, 1486.e9

    CrossRef

  30. 30
    Clive Ballard, Serge Gauthier, Anne Corbett, Carol Brayne, Dag Aarsland, Emma Jones, Alzheimer's disease, The Lancet, 2011, 377, 9770, 1019

    CrossRef

  31. 31
    Jonathan M Schott, Combining biomarkers: the future for Alzheimer’s disease prevention studies?, Neurodegenerative Disease Management, 2011, 1, 3, 175

    CrossRef

  32. 32
    Valérie Leduc, Dorothée Domenger, Louis De Beaumont, Daphnée Lalonde, Stéphanie Bélanger-Jasmin, Judes Poirier, Function and Comorbidities of Apolipoprotein E in Alzheimer's Disease, International Journal of Alzheimer's Disease, 2011, 2011, 1

    CrossRef

  33. 33
    Lucilla Parnetti, Davide Chiasserini, Role of CSF biomarkers in the diagnosis of prodromal Alzheimer’s disease, Biomarkers in Medicine, 2011, 5, 4, 479

    CrossRef

  34. 34
    R. A. Sperling, C. R. Jack, P. S. Aisen, Testing the Right Target and Right Drug at the Right Stage, Science Translational Medicine, 2011, 3, 111, 111cm33

    CrossRef